USFDA Warns Dabur Over Silvassa Plant Lapses

The US Food and Drug Administration (USFDA) has issued a warning letter to Dabur India, citing serious manufacturing and quality control lapses at its pharmaceutical facility in Silvassa, Dadra and Nagar Haveli and Daman and Diu. The warning follows an inspection conducted by the US health regulator at the company's manufacturing unit.

The USFDA said the facility failed to meet required standards under the US Federal Food, Drug and Cosmetic Act, making products manufactured there liable to be considered 'adulterated'. The regulator highlighted several violations, including data integrity failures, inadequate quality oversight, and deficiencies in manufacturing controls.

One of the major findings involved alleged falsification of an equipment usage logbook. The USFDA said a document submitted by the company for a manufacturing line had intentionally excluded details of multiple over-the-counter products sold in the US. The original records containing the missing information were later found in the facility's document room.

The regulator also pointed out deficiencies in laboratory operations, stating that analytical records were incomplete and supporting documentation, including test procedures, workbooks, and data sheets for certain batches, was unavailable. Issues were also identified in microbiological testing records and equipment documentation.

The USFDA further criticized Dabur's cleaning validation process for shared manufacturing equipment, saying it relied mainly on visual checks without scientifically established residue limits and adequate testing procedures. The regulator also noted that process validation had not been completed for several OTC products manufactured at the facility.

Dabur responded to the observations by committing to corrective steps, including employee retraining, improved documentation practices, and strengthening cleaning validation systems. However, the USFDA termed the response inadequate, stating that it did not sufficiently address the broader systemic issues.

The warning letter is a significant concern for Dabur, as it may impact the company's ability to export products to the US. The USFDA's findings also raise questions about the company's compliance with current good manufacturing practices (CGMP).

Dabur India CEO Mohit Malhotra has been asked to take immediate action to address the issues raised by the USFDA. The company has committed to implementing corrective measures, but the USFDA's warning letter is a clear indication that more needs to be done to ensure compliance with regulatory standards.

The incident highlights the importance of maintaining high standards of quality control and manufacturing practices in the pharmaceutical industry. The USFDA's strict regulations are in place to ensure the safety and efficacy of products, and companies must adhere to these standards to avoid regulatory action.

In conclusion, the USFDA's warning letter to Dabur India is a significant development that highlights the need for the company to strengthen its compliance with regulatory standards. The incident serves as a reminder of the importance of maintaining high standards of quality control and manufacturing practices in the pharmaceutical industry.

The warning letter may have implications for Dabur's business, particularly its exports to the US. The company must take immediate action to address the issues raised by the USFDA and ensure that its manufacturing practices meet the required standards.

The USFDA's action is a testament to the regulator's commitment to ensuring the safety and efficacy of products. The warning letter serves as a reminder to pharmaceutical companies of the importance of complying with regulatory standards and maintaining high standards of quality control and manufacturing practices.